Latest / Taylor Tailored / Drugmakers raise US prices on 350 medicines as Trump's pressure collides with the pricing system
Transcript
- 0:00Drug makers raise US Prices on 350 Medicines As Trump's
- 0:04pressure collides with the pricing system As of December
- 0:0831st, 2025, drug makers are preparing to raise list prices
- 0:13in the United States on at least 350 branded medicines starting
- 0:18January 1st, 2026. The moves land in the middle of
- 0:22a political campaign to show relief on everyday costs, and
- 0:26they put a spotlight back on why US drug prices remain so
- 0:31difficult to steer. The immediate tension is simple.
- 0:34The White House is pushing companies to cut what Americans
- 0:37pay, yet manufacturers are still lifting published prices across
- 0:41vaccines, cancer drugs and common therapies.
- 0:44Some firms are also cutting prices on a small set of
- 0:47medicines at the same time, creating a confusing mix that
- 0:51looks like progress and provocation.
- 0:53In one snapshot. This piece explains what is
- 0:56changing on January 1st, what list price increases do and do
- 1:01not mean in a rebate driven system, and why both parties can
- 1:05claim they are lowering prices while patients still feel
- 1:08squeezed. The story turns on whether
- 1:10political pressure can change the incentives that make higher
- 1:14list prices a rational choice. Key Points Drug makers plan list
- 1:19price increases on at least 350 branded medicines starting
- 1:24January 1st, 2026 with a median increase around 4%.
- 1:29The set of planned increases is larger than this time last year
- 1:33even as the administration highlights most favored nation
- 1:37style pricing agreements and direct to consumer initiatives.
- 1:41The headline numbers reflect list prices, not the behind the
- 1:45scenes rebates and discounts that shape what insurers and
- 1:48pharmacy middle men actually pay.
- 1:51Some manufacturers are cutting list prices on a small number of
- 1:54medicines, including a major reduction for the diabetes drug
- 1:58Jardiance tied to Medicare's first negotiated prices that
- 2:01begin in 2026. Pfizer accounts for the biggest
- 2:05cluster of increases, including a notable jump for its COVID
- 2:09vaccine, while many other increases stay under 10%.
- 2:13The biggest real world exposure is for people who pay based on
- 2:16list price mechanics, the uninsured, patients in high
- 2:20deductible plans, and those with coinsurance tied to a drug.
- 2:24Sticker Price Background List price is the published sticker
- 2:28price of a medicine, often described as a wholesale
- 2:31acquisition cost. In the United States, that
- 2:35number is rarely what large insurers pay after rebates, and
- 2:39it is even less likely to be what a patient pays at the
- 2:42pharmacy counter if they have adequate coverage.
- 2:45But list price still matters because it sets the starting
- 2:48point for rebates, influences what some patients pay in
- 2:52deductibles and coinsurance, and shapes negotiations across the
- 2:55supply chain. A key player in that supply
- 2:58chain is the pharmacy benefit manager, or PBM.
- 3:02PBMS help employers and insurers run drug benefits, negotiate
- 3:06rebates, decide which medicines get preferred placement on
- 3:10formularies and determine what patients pay at the point of
- 3:14sale. That structure can reward high
- 3:16list prices paired with large rebates, because rebates are
- 3:20often the currency used to secure coverage and market
- 3:23share. At the same time, federal policy
- 3:26has started to narrow the space for big annual price hikes.
- 3:29Medicare now penalizes certain price increases that outpace
- 3:33inflation, and the first set of Medicare negotiated prices for
- 3:37selected high spend drugs is scheduled to take effect on
- 3:40January 1st, 2026. That mix can push companies to
- 3:44be more cautious about repeated post launch hikes, while also
- 3:49increasing the stakes around launch prices and list price
- 3:52strategy. In the commercial market,
- 3:54January is also the traditional reset point.
- 3:57Many drug price changes in the US system are timed for January
- 4:001, when contracts renew and benefit designs reset, making
- 4:05the first week of the year a recurring flashpoint in the
- 4:08politics of affordability analysis, political and
- 4:12geopolitical dimensions. The administration's pressure
- 4:15campaign is built around a public promise Americans should
- 4:19not pay dramatically more than patients in other wealthy
- 4:22countries for the same medicines.
- 4:24That message is politically potent because high prescription
- 4:27costs have become a durable cost of living symbol across party
- 4:31lines. But the conflict is not only
- 4:33domestic. Most Favored nation language
- 4:36implicitly compares US prices to those in peer countries.
- 4:40And any attempt to force US prices down raises a second
- 4:43order question. Who absorbs the difference?
- 4:47Drug makers argue that overseas price setting systems free ride
- 4:50on US funded innovation, while critics argue that US patients
- 4:55are subsidizing global profit margins through a uniquely
- 4:58permissive pricing environment. That geopolitical framing can
- 5:02harden positions. It turns price cuts into a
- 5:05sovereignty argument, and it gives manufacturers A narrative
- 5:09that price pressure threatens future research.
- 5:11It also makes wins easier to stage.
- 5:14Targeted discounts, limited scope agreements or direct to
- 5:18consumer offerings can be framed as transformation, even if the
- 5:22system's baseline incentives remain intact.
- 5:26Scenarios to watch. A tougher enforcement posture
- 5:29that ties federal contracting, tariffs, or procurement
- 5:32preferences to lower US prices. A negotiated equilibrium where
- 5:37companies offer selective cuts for government programs while
- 5:40maintaining commercial pricing power.
- 5:42Legal and regulatory friction that slows or narrows the reach
- 5:46of price controls, pushing the fight into courts and agencies
- 5:50rather than pharmacies. Economic and market impact.
- 5:54The planned increases are mostly modest in percentage terms, but
- 5:58they compound. A 4% median hike repeated year
- 6:01after year, is the kind of quiet inflation that rarely makes a
- 6:05household headline until it hits a deductible or an unexpected
- 6:09prescription. The market impact also depends
- 6:12on how much of the increase sticks as net revenue.
- 6:15In many cases, manufacturers raise list prices while also
- 6:19increasing rebates to secure formulary position that can keep
- 6:23net prices flatter than list prices even while patients who
- 6:27pay cost sharing based on list price feel the full force of the
- 6:31sticker shock. Another pressure point is the
- 6:34split between retail and hospital administered medicines.
- 6:38When a low cost hospital drug jumps sharply in percentage
- 6:41terms, it may still be small in absolute dollars, but it can
- 6:45disrupt purchasing and amplify public outrage because it looks
- 6:49like gouging. Meanwhile, big ticket specialty
- 6:52drugs can rise only a few percent and still move
- 6:56meaningful money scenarios to watch.
- 6:59Insurers respond by shifting formularies, tightening prior
- 7:02authorization, or raising premiums and cost sharing to
- 7:07offset higher gross costs. Employers push harder for point
- 7:11of sale rebate pass through models that reduce patient
- 7:14exposure to list prices. Investors reward predictable
- 7:17pricing power, reinforcing the incentive to treat list price
- 7:22increases as routine unless regulation imposes real
- 7:26downside. Social and cultural fallout.
- 7:30For many Americans, the drug pricing story is not abstract.
- 7:34It is a monthly ritual. The refill that suddenly costs
- 7:37more, the new Co insurance math in January, the phone calls to
- 7:41insurers, the search for coupons and the decision to delay or
- 7:45skip doses. The burden falls unevenly.
- 7:49People with stable coverage may barely notice.
- 7:52Others, especially those in high deductible plans early in the
- 7:55year, can see sharp out of pocket spikes tied directly to
- 7:59list price. The uninsured can face the
- 8:02starkest version of the system, where the published price is the
- 8:06starting point and the discounts are opaque or inconsistent.
- 8:10The cultural impact is broader than health.
- 8:12It feeds distrust in institutions, resentment toward
- 8:16corporate power and a sense that basic life needs are being
- 8:19priced like luxury goods. It also intensifies a familiar
- 8:23political cycle. Outrage in January, hearings in
- 8:26spring. Incremental reforms and another
- 8:29January reset. Scenarios to watch.
- 8:32Increased state level action targeting PBM practices.
- 8:36Spread pricing and rebate transparency.
- 8:39Greater adoption of direct to consumer purchasing models,
- 8:43which could help some patients but also risks fragmenting
- 8:46access. A stronger backlash against the
- 8:49idea that rebates are savings when the sticker price keeps
- 8:52rising. Technological and security
- 8:55implications. Drug pricing is increasingly a
- 8:58data problem. Benefit design, rebate contracts
- 9:01and coverage decisions are now mediated by software platforms
- 9:06and algorithmic utilization management.
- 9:09That can improve efficiency, but it can also make the system feel
- 9:12like a black box to patients and clinicians.
- 9:15Direct to consumer channels, including manufacturer platforms
- 9:19and cash pay programs, are also expanding.
- 9:22They can create real savings for some people, particularly those
- 9:26who fall through coverage cracks.
- 9:28But they also introduce new risks.
- 9:30Fragmented pricing, confusing eligibility rules, and the
- 9:34possibility that patients will be steered into pathways that
- 9:38optimize corporate strategy rather than continuity of care.
- 9:42There is also a resilience angle.
- 9:44When pricing pressure meets supply constraints, the risk of
- 9:48shortages and discontinuations rises for certain products,
- 9:52especially older generics or low margin hospital drugs.
- 9:56Pricing policy and supply security are not the same
- 9:59problem, but they increasingly touch scenarios to watch.
- 10:03More transparency mandates that standardize how discounts and
- 10:07net prices are reported. Stronger cybersecurity and
- 10:11privacy scrutiny as more patients buy medicines through
- 10:15online manufacturer channels. Policy that ties pricing reforms
- 10:19to supply chain resilience, especially for essential
- 10:22medicines. What most coverage misses The
- 10:25loudest debate often treats price hikes as a single lever,
- 10:28but the system runs on multiple price layers.
- 10:31A list price increase can be real pain for patients, even if
- 10:34net prices stay flat. And a price cut can be real
- 10:38politics even if it applies to a narrow segment or is offset
- 10:42elsewhere. The second blind spot is that
- 10:45the biggest long run driver of spending is often not annual
- 10:49increases on existing drugs. It is launch prices, market
- 10:53exclusivity and the slow pace of genuine competition in many
- 10:58therapeutic categories. Annual hikes are the visible
- 11:01tip. The structure underneath decides
- 11:04whether the tip matters. If the policy goal is to lower
- 11:07what people pay, then the most important question is not how
- 11:11many drugs have list price changes on January 1st.
- 11:14It is whether reforms reduce the number of patients whose out of
- 11:17pocket costs are calculated from inflated sticker prices in the
- 11:211st place. Why this matters In the short
- 11:24term, January 1 is the pressure test.
- 11:27That is, when new list prices kick in, deductibles reset and
- 11:30patients discover whether their plan design Shields them or
- 11:34exposes them. The same week also sets the tone
- 11:37for the year's political messaging on affordability.
- 11:40In the longer term, 2026 is a hinge year because Medicare's
- 11:45first negotiated prices on selected drugs are scheduled to
- 11:49take effect. That creates a new reference
- 11:52point for what lower prices can look like in a major federal
- 11:55program, and it may change how manufacturers think about
- 11:58pricing strategy in commercial markets.
- 12:01Events and signals to watch next.
- 12:04Additional manufacturer announcements in early January,
- 12:07when the largest share of annual price adjustments typically
- 12:10appear. The rollout details and uptake
- 12:12of direct to consumer purchasing options promoted by the
- 12:15administration. Insurer and employer Benefit
- 12:18changes for 2026 that determine whether rebates are reflected at
- 12:23the pharmacy counter or absorbed elsewhere in the system.
- 12:26Real world impact A retiree in Florida with multiple chronic
- 12:30conditions hits a January deductible and finds that
- 12:34coinsurance is calculated from a higher list price.
- 12:37Their plan still covers the medicine, but the first few
- 12:40refills of the year feel like a sudden pay cut.
- 12:43A self-employed contractor in Texas loses employer coverage
- 12:46and shops for a cash price. The list price increase matters
- 12:50immediately because discounts vary by pharmacy and the best
- 12:55price depends on which program they can access that month.
- 12:58A hospital pharmacist in Illinois sees a sharp price jump
- 13:02for an older injectable pain medicine.
- 13:05The absolute cost is not enormous, but the procurement
- 13:08disruption forces substitutions and tightens inventory planning.
- 13:12A middle income family in California is told a vaccine is
- 13:16recommended, but the out of pocket cost rises.
- 13:19They delay not because they oppose vaccination, but because
- 13:23the timing collides with rent, groceries and a New Year's
- 13:27budget reset. What's next?
- 13:29The January 1 changes will spark familiar outrage, but the
- 13:33biggest story is the tug of war between political messaging and
- 13:37pricing mechanics. List price hikes can look like
- 13:39defiance, yet they can still fit inside a system where rebates
- 13:44and net prices do the real financial work behind closed
- 13:47doors. If the administration wants
- 13:50durable wins, it has to change what patients are exposed to,
- 13:54not just what manufacturers publish.
- 13:56That means benefit design, PBM incentives and the rules that
- 14:00decide whether rebates reach the pharmacy counter.
- 14:03The key sign will be whether 2026 brings a measurable drop in
- 14:07out of pocket costs for the group's most exposed to list
- 14:11prices, the uninsured, the underinsured and people whose
- 14:15cost sharing is tied directly to sticker prices.
- 14:18If those patients see relief, the politics will shift.
- 14:21If they do not, the system will keep producing the same January
- 14:25shock no matter how many deals are announced in December.